Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant toripalimab + chemotherapy + thermal ablation in resectable NSCLC (Phase II)
ChiCTR2500111260Phase 2Not yet recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Beijing Friendship Hospital. Primary endpoint: Pathological complete response (pCR). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500111260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111260.